Labiotech.eu

News and Trends 30 Mar 2017

New Clues on How the Immune System Weakens with Age

By analyzing the responses of individual immune cells, a new study in Science provides new insights into the decline of the immune system with age. In a collaborative effort, researchers from the European Bioinformatics Institute (EMBL-EBI), University of Cambridge, the Wellcome Trust Sanger Institute and the Cancer Research UK–Cambridge Institute (CRUK-CI) have shed light on a […]

March 30, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 30 Mar 2017

Merck Outsources the Development of its Nanobody for Psoriasis

Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody […]

March 30, 2017 - 3 minutesmins - By Melanie De Almeida

Regeneron Sanofi dupilumab Atopic Dermatitis

News and Trends 29 Mar 2017

Get Ready for One of the Biggest New Drug Approvals of the Year

After Praluent, Sanofi and Regeneron have now scored their next drug approval with dupilumab, an antibody for the treatment of atopic dermatitis. With three placebo-controlled clinical trials enrolling a total of 2119 adult participants, Sanofi and its partner Regeneron were able to convince the FDA of their new biological for the treatment of atopic dermatitis. The product of this expansive effort comes […]

March 29, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 29 Mar 2017

More “FDA Love” for Cannabis Company with Orphan Drug Designation

Last year was a doozy for biotech, but it was spectacular for GW Pharmaceuticals. Its streak continues with more special treatment. GW Pharmaceuticals, which is developing epilepsy treatments from marijuana, is making a name for itself not just as “that company” turning a recreational drug into medical ones; the company was also one of 2016’s surprise successes — its […]

March 29, 2017 - 2 minutesmins - By Evelyn Warner

Lysogene gene therapy Sanfillipo A obs study

News and Trends 29 Mar 2017

French Gene Therapy Biotech Gets Ready for Phase II/III

Lysogene has crunched the numbers on its observational study for Sanfillipo A – now the company can move into the final phase for its Sanfilippo A therapy. Lysogene is a French biotech specializing in gene therapy of rare CNS diseases. Its lead asset is a gene therapy for the treatment of the rare genetic disorder […]

March 29, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 29 Mar 2017

Looking to Patent your Biotech Invention? Here’s What You Need to Know

So you’ve made a discovery you want to protect or an invention you want to commercialize. How do you claim intellectual property? Patents are the most relevant kind of intellectual property protection for technology-driven industries, particularly high-tech startups. They grant intellectual property rights covering technical inventions and relate to compositions, processes or methods of making these, or their use for a particular purpose. More […]

March 29, 2017 - 4 minutesmins - By External Contributor

European Patent Office CRISPR Decision 1

News and Trends 28 Mar 2017

Europe Turns the Tables in the CRISPR Patent Battle

ERS Genomics has announced that the EPO intends to grant a patent with broad claims covering the use of CRISPR to Emmanuelle Charpentier. ERS Genomics has announced that the European Patent Office (EPO) will grant its founder, Emmanuelle Charpentier as well as the University of Vienna and University of California, Berkeley, a patent covering the broad use of CRISPR-Cas9 […]

March 28, 2017 - 3 minutesmins - By Melanie De Almeida

Numab Ono Pharmaceutical Immuno Oncology

News and Trends 28 Mar 2017

Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster

Ono Pharmaceutical is offering the Swiss Numab €241M (CHF 258M) for the development of a multi-specific antibody for immuno-oncology applications. Numab, one of the hottest biotechs in Zurich, has developed a unique technology to generate stable antibody fragments (not an easy feat!) and use them as building blocks for multi-specific antibodies that can target up […]

March 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Mar 2017

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […]

March 28, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 27 Mar 2017

You Can Now Search Worldwide Genomic Data in a Single Platform

Access to data is still the main bottleneck for genomic researchers. Repositive has created a free online platform to solve this problem once and for all. Repositive is building an online platform that makes genomic data from different sources easily searchable and accessible from a single portal. Its mission is to speed up genetic diagnostics […]

March 27, 2017 - 5 minutesmins - By External Contributor

Interview 27 Mar 2017

Meet one of the Most Successful Biotech Entrepreneurs in the UK

Jonathan Milner is a rockstar biotech entrepreneur and founder of Abcam. He is still on the board of his baby Abcam, while investing in many young startups, nurturing the British biotech ecosystem and taking part in philanthropy. Here’s my chat with him on all these topics. “I was amazed by how you could order books […]

March 27, 2017 - 7 minutesmins - By Philip Hemme

News and Trends 24 Mar 2017

Novartis puts the Development of two Anti-Aging Drugs in American Hands

PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio of PureTech, a Boston-based healthcare company listed on the London stock market. Originally an investment firm, it now has put together a drug pipeline from […]

March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New Clues on How the Immune System Weakens with Age

Merck Outsources the Development of its Nanobody for Psoriasis

Get Ready for One of the Biggest New Drug Approvals of the Year

More “FDA Love” for Cannabis Company with Orphan Drug Designation

French Gene Therapy Biotech Gets Ready for Phase II/III

Looking to Patent your Biotech Invention? Here’s What You Need to Know

Europe Turns the Tables in the CRISPR Patent Battle

Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

You Can Now Search Worldwide Genomic Data in a Single Platform

Meet one of the Most Successful Biotech Entrepreneurs in the UK

Novartis puts the Development of two Anti-Aging Drugs in American Hands

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!